DescriptionCurator's Comment:: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Curator's Comment:: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 30.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1.46102403E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cutaneous vasculitis due to ciprofloxacin. | 1992 Jul 4 |
|
| Concentration-dependent preferences of absorptive and excretive transport cause atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compounds. | 2002 |
|
| Effect of composition on the physicochemical properties and active substance release from gelatin-alginate sponge. | 2003 |
|
| Treatments for symptomatic urinary tract infections during pregnancy. | 2003 |
|
| Synthesis and antibacterial activity of cephradine metal complexes: part I complexes with magnesium, calcium, chromium and manganese. | 2003 Jan |
|
| Concentration-dependent atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compounds. | 2003 Nov |
|
| Microbiology and drug sensitivity patterns of chronic suppurative otitis media. | 2004 Aug |
|
| Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. | 2004 Feb |
|
| Molecularly imprinted solid phase extraction-pulsed elution-mass spectrometry for determination of cephalexin and alpha-aminocephalosporin antibiotics in human serum. | 2004 Nov 15 |
|
| Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics. | 2004 Sep |
|
| Re: "Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol" Solis et al. (Pediatr Pulmonol 2003;36: 189-195). | 2004 Sep |
|
| Nateglinide uptake by a ceftibuten transporter in the rat kidney brush-border membrane. | 2005 Aug 30 |
|
| Synthesis and antibacterial activity of cephradine metal complexes : part II complexes with cobalt, copper, zinc and cadmium. | 2005 Jan |
|
| Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. | 2005 Jan |
|
| H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine. | 2005 Jan |
|
| Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans. | 2005 Mar |
|
| Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography. | 2005 Mar-Apr |
|
| Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. | 2005 Sep 14 |
|
| Properties and active substance release kinetics from gelatin-alginate matrices. | 2006 |
|
| [Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases]. | 2006 Apr |
|
| A case of inadvertent anterior chamber and corneal stromal injection with antibiotics during cataract operation. | 2006 Dec |
|
| A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean. | 2006 Feb 13 |
|
| Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction. | 2006 Jul-Aug |
|
| Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. | 2007 Jul 15 |
|
| Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. | 2007 Oct |
|
| Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells. | 2008 Apr 16 |
|
| A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008 Aug |
|
| Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008 Dec |
|
| Cranial osteomyelitis: a late complication of a dental infection. | 2008 Dec |
|
| [Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial]. | 2008 Jan 15 |
|
| Aeromonas salmonicida peritonitis after eating fish in a patient undergoing CAPD. | 2008 May-Jun |
|
| Pharmacokinetic study of cephradine in Pakistani healthy male volunteers. | 2008 Oct |
|
| Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations. | 2009 |
|
| Antibiotic susceptibility of thermo-tolerant Escherichia coli 2 isolated from drinking water of Khairpur City, Sindh, Pakistan. | 2009 Apr 15 |
|
| A study of the chemiluminescence behavior of cephalosporins with luminol and its analytical application. | 2009 Aug |
|
| [Analysis of multiple cephalosporins in blood and urine by HPLC]. | 2009 Dec |
|
| [Kneading and dispersing manipulation in treatment of early-stage acute mastitis: a randomized controlled trial]. | 2009 Dec |
|
| Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study. | 2009 Dec 1 |
|
| [Study of cefadroxil and cephradine charge transfer process by fluorescence quenching method]. | 2009 Feb |
|
| Antibiotic susceptibility pattern of Staphylococcus epidermidis. | 2009 Jul |
|
| [Microcalorimetric investigation of two cephalosporins on colon bacteria activity]. | 2009 Oct |
|
| [Antibiotic consumption and antimicrobial susceptibility evolution in the Centro Hospitalario Pereira Rossell in methicillin resistant Staphylococcus aureus era]. | 2009 Oct |
|
| Traumatic optic neuropathy accompanying orbital grease gun injury. | 2010 Apr |
|
| Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles. | 2010 Apr 15 |
|
| Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns. | 2010 Jan |
|
| Selective densitometric determination of four alpha-aminocephalosporins using ninhydrin reagent. | 2010 Jan |
|
| A survey of the management of urinary tract infection in children in primary care and comparison with the NICE guidelines. | 2010 Jan 26 |
|
| Uropathogen resistance to antibiotic prophylaxis in urinary tract infections. | 2010 Jun |
|
| Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia. | 2010 Mar-Apr |
|
| Rhinoscleroma: case report. | 2010 Sep-Oct |
Patents
Sample Use Guides
For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours.
For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered.
Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration:
Oral
| Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Jun 25 20:52:02 UTC 2021
by
admin
on
Fri Jun 25 20:52:02 UTC 2021
|
| Record UNII |
F1BC02I72W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01DB09
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
||
|
LIVERTOX |
178
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
||
|
NDF-RT |
N0000175488
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C47441
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
SUB21808
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
D002515
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
CHEMBL1604
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
F1BC02I72W
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
1102805
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | USP-RS | ||
|
SUB07417MIG
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
4830
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | |||
|
2239
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY | RxNorm | ||
|
Cephradine
Created by
admin on Fri Jun 25 20:52:02 UTC 2021 , Edited by admin on Fri Jun 25 20:52:02 UTC 2021
|
PRIMARY |
Any of these components may be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
|
TRANSPORTER -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||